Health Insurance Industry Issues and Legislation

End-Stage Renal Disease (ESRD) remains one of the most expensive recurring conditions facing self-funded health plans. In this case, a 56-year-old male patient's dialysis treatments exceeded $833,000 in billed charges.

Instead of using a traditional ESRD dialysis program that charges a percentage of savings throughout the 30-month coordination period, H.H.C. Group applied its Medicare-benchmarked Reference-Based Pricing strategy and $300 per treatment flat-fee model. The result: a 90.1% reduction in total liability — with predictable pricing and no erosion of savings through ongoing percentage-based fees.

Provider Charges: $833,054.41
Repriced Amount: $39,329.62
Flat-Fee Total (144 treatments): $43,200.00
Net Plan Savings: $750,524.79 (90.1%)

Results:

• 90.1% cost reduction on a high-dollar claim
• Transparent, flat-fee dialysis pricing
• No balance billing for the patient

Many ESRD programs reduce charges — then take a percentage of those savings for up to 30 months. That structure strips value away from the plan long after initial negotiations are complete.

H.H.C. Group's flat-fee model ensures the savings stay with the plan — not the vendor. Recurring dialysis claims can quietly drain plan assets year after year.

Contact H.H.C. Group to review your ESRD claims strategy and see how a flat-fee, Medicare-aligned approach can deliver predictable pricing and substantial savings.

Catastrophic claims are no longer rare — and stop-loss coverage alone isn't enough to protect today's self-funded plans. In a recent article, Bruce D. Roffé explains why brokers and employers must pair stop-loss with proactive claim negotiation, detailed bill review and independent clinical validation to reduce spend before claims breach deductibles and trigger long-term premium pressure. In today's environment, disciplined, expert-led oversight is what separates protected plans from exposed ones.

Read the full article and explore smarter strategies for managing high-cost claims.

A recent Supreme Court decision declining to expand enforcement of No Surprises Act IDR awards reinforces a critical point for payors and stop-loss carriers: dispute mechanisms are not a safety net for missed claim oversight. Once high-cost out-of-network claims are finalized, leverage narrows and recovery options become limited — making early, expert-led review and negotiation more essential than ever.

Cardiology claims often involve layered coding, multiple providers, implants, and billing practices that survive PPO discounts while still exceeding what's fair or defensible.

Read the full blog to understand what this ruling means for your high-cost claim strategy — and how proactive oversight protects plan assets before options disappear.

Hospitals accounted for 40% of U.S. health care spending growth between 2022 and 2024, nearly double the next-largest category, according to new KFF data. National health expenditures reached $5.3 trillion in 2024, with hospital spending rising 20% and now representing a growing share of GDP. As hospital prices and outpatient utilization climb, employer premiums and plan costs continue to feel the impact.

With hospital costs driving claim severity higher, now is the time to strengthen claim review and negotiation strategies — contact H.H.C. Group to protect your plan from inflated facility charges.

Sun Life raised employer stop-loss renewal rates 17% in 2026, yet still grew stop-loss sales 56% year over year — reflecting both rising catastrophic claim severity and strong employer demand for financial protection. Executives cited escalating large-claim costs and market consolidation, with some smaller competitors pulling back due to limited scale. The trend signals continued premium pressure for self-funded plans as multimillion-dollar claims become more routine.

As stop-loss costs rise, now is the time to strengthen your claim oversight strategy — contact H.H.C. Group to ensure high-cost claims are reviewed, negotiated and managed before they impact renewals.